| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT06097728 MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural… |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-10 | NCT06097728 MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural… |
Trial sites reduced: 178 -> 151 locations |
| 2026-06-10 | NCT06097728 MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural… |
date change Primary completion pushed: 2027-11-19 -> 2028-11-16 |
| 2026-05-27 | NCT06535607 Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in… |
Trial sites expanded: 59 -> 95 locations |
| 2026-05-20 | NCT06943833 A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) |
Enrollment increased: 30 -> 37 participants |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06129864 | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally… | Locally Advanced Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT06079671 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer… | Locally Advanced Cervical Cancer | Recruiting |
| NCT07000149 | A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab +… | Advanced Clear Cell Renal Cell Carcinoma | Active, Not Recruiting |
| NCT05984277 | A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus… | Metastatic Non-small Cell Lung Cancer | Active, Not Recruiting |
| NCT06097728 | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural… | Unresectable Pleural Mesothelioma | Active, Not Recruiting |
| Phase 2 | |||
| NCT07065630 | Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer | Head and Neck Cancer | Recruiting |
| NCT05489211 | Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients… | Endometrial Cancer | Recruiting |
| NCT05775159 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents… | Hepatocellular Carcinoma | Recruiting |
| NCT06792695 | A Study of Novel Study Interventions and Combinations in Participants With Colorectal… | Metastatic Colorectal Cancer | Recruiting |
| NCT05702229 | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic… | Gastric Cancer | Recruiting |
| NCT05061550 | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | Recruiting |
| NCT06535607 | Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in… | Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) | Recruiting |
| NCT04379596 | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing… | Gastric Cancer | Recruiting |
| NCT06448754 | Volrustomig Priming Regimens Exploratory Phase II Platform Study | Non-small Cell Lung Cancer | Recruiting |
| NCT06943833 | A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) | Locally Advanced Cervical Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without… | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Recruiting |
| NCT04612751 | Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin… | Advanced or Metastatic NSCLC | Active, Not Recruiting |
| NCT03819465 | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC | Metastatic Non-Small Cell Lung Cancer (NSCLC) | Active, Not Recruiting |
| NCT03530397 | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | Selected Advanced Solid Tumors | Active, Not Recruiting |
| Early Phase 1 | |||
| NCT04541108 | Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | Solid Tumor | Active, Not Recruiting |